5 May, 2023
CLS Americas and Unio Health Partners Announce Clinical Study
We are happy to share that CLS Americas has entered into an agreement with Genesis Research, LLC, an affiliate of Unio Health Partners, to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”
Read more
13 April, 2023
CLS Americas Announces Research Collaboration with the National Institutes of Health Clinical Center
Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.
Read more
21 March, 2023
NEW: Animation showing Fusion-guided Focal Laser Ablation in Prostate Cancer
We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.
Read more
21 March, 2023
Post-Market Study to Evaluate CLS’s TRANBERG Thermal Therapy System by HALO Dx
We are happy to share that HALO Diagnostics, Inc. (HALO Dx) will evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients.
Read more
6 February, 2023
CLS Americas and URN Announce Treatment of 20th & Final Patient in Clinical Study
CLS Americas announces the full twenty patients have been safely treated in the Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”
Read more
28 November, 2022
Clinical data from a Phase II trial using CLS TRANBERG products presented during RSNA 2022 Annual Meeting
The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.
Read more
2 November, 2022
Interview with our CTO and VP Clinical Affairs – How CLS contributes to better treatment of Prostate Cancer
Our CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik, explain how the TRANBERG® Thermal Therapy Systems have been designed for precise and safe focal therapy of soft tissue, such as the prostate gland, and what kind of research CLS is now supporting.
Read more
1 November, 2022
CLS Supports Movember - Introduction by CEO Dan J. Mogren
CEO Dan J. Mogren introduces our support for Movember. This annual campaign is all about raising awareness around male health, and specifically around prostate cancer.
It is one of the most common cancer forms among men, but more can be done to spread knowledge about the disease.
Read more
17 October, 2022
Demonstration of Targeted Focal Therapy with Fusion-guided Laser Ablation by Dr. Fernando J. Bianco
Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.
Read more
26 September, 2022
CLS receives FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery
We are proud to announce that CLS has received FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery!
Read more
22 September, 2022
CLS Americas & Focalyx Present Integrated Fusion-Guided Focal Laser Ablation Solution at FOCAL 2022 Conference
Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.
Read more
21 April, 2022
CLS Americas and URN Announce First Patient Treated in Clinical Study “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer”
CLS Americas today announced the first patient has been safely treated in its recently announced 20-patient, Phase I clinical study.
Read more
5 April, 2022
CLS Americas Inc. and URN Announce Clinical Study “Targeted MRI/US Fusion Transperineal Laser Ablation of Low to Intermediate Risk Prostate Cancer”
Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”
Read more
18 February, 2022
Radboud University Medical Center (Nijmegen, NL) has initiated a clinical trial using the CLS TRANBERG® products for patients with prostate cancer
Radboud University Medical Center (Radboudumc) in Nijmegen in the Netherlands has obtained approval from its ethics committee for its Investigator Initiated Trial (IIT) to evaluate the safety and feasibility of magnetic resonance guided focused laser ablation (MRgFLA) as a focal therapy treatment for localized prostate cancer in low to intermediate risk patients, using the TRANBERG® Thermal Therapy System with Thermoguide™ Workstation.
Read more